このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Perspective Therapeutics マネジメント

マネジメント基準チェック /14

Perspective Therapeutics'の CEO はThijs Spoorで、 Feb2023年に任命され、の在任期間は 1.33年です。の年間総報酬は$ 1.46Mで、 34.7%給与と65.3%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.031%を直接所有しており、その価値は$ 214.61K 。経営陣と取締役会の平均在任期間はそれぞれ1.3年と1.3年です。

主要情報

Thijs Spoor

最高経営責任者

US$1.5m

報酬総額

CEO給与比率	34.7%
CEO在任期間	1.4yrs
CEOの所有権	0.03%
経営陣の平均在職期間	1.4yrs
取締役会の平均在任期間	1.4yrs

経営陣の近況

Recent updates

CEO報酬分析

Perspective Therapeutics の収益と比較して、Thijs Spoor の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$50m
Dec 31 2023	US$1m	US$506k	-US$37m

報酬と市場: Thijsの総報酬 ($USD 1.46M ) は、 US市場 ($USD 3.39M ) の同様の規模の企業の平均を下回っています。

報酬と収益: Thijsの報酬と会社の業績を比較するにはデータが不十分です。

CEO（最高経営責任者

Thijs Spoor (52 yo)

1.4yrs

在職期間

US$1,458,996

報酬

Mr. Johan M. Spoor, also known as Thijs, is Chief Executive Officer and Director at Perspective Therapeutics, Inc. (formerly known as Isoray, Inc.) since February 05, 2023. He founded AzurRx BioPharma, Inc...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Johan Spoor	CEO & Director	1.4yrs	US$1.46m	0.031% $ 223.1k
Jonathan Hunt	CFO & Co-Principal Financial Officer	5.6yrs	US$1.17m	0.053% $ 386.7k
Markus Puhlmann	Chief Medical Officer	1.4yrs	US$900.09k	0.20% $ 1.5m
Shane Cobb	Executive Vice President of Operations	less than a year	データなし	データなし
Mark Austin	VP of Finance	7yrs	データなし	0.012% $ 90.3k
Michael Schultz	Chief Science Officer	no data	データなし	2.2% $ 15.9m
Andrew Bright	Executive Vice President of Brachytherapy	1.3yrs	データなし	データなし
Amos Hedt	Chief Business Strategy Officer	no data	データなし	データなし
Frances Johnson	Chief Innovation Officer	no data	データなし	2.2% $ 15.9m
David Hauser	Senior Vice President of Clinical Operations	no data	データなし	データなし

1.4yrs

平均在職期間

54.5yo

平均年齢

経験豊富な経営陣: CATXの経営陣は経験豊富とはみなされません ( 1.3年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Johan Spoor	CEO & Director	1.4yrs	US$1.46m	0.031% $ 223.1k
Robert Williamson	Independent Director	1.4yrs	US$320.06k	0.063% $ 459.5k
Frank Morich	Independent Director	1.4yrs	US$320.06k	データなし
Heidi Henson	Independent Director	1.1yrs	US$390.70k	データなし
Lori Holmes-Woods	Chairperson of the Board	6.1yrs	US$671.73k	0.24% $ 1.8m

1.4yrs

平均在職期間

58yo

平均年齢

経験豊富なボード: CATXの取締役会は経験豊富ではない ( 1.3年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Perspective Therapeutics マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

CFO & Co-Principal Financial Officer recently bought US$177k worth of stock

CEO & Director recently bought US$117k worth of stock

Perspective Therapeutics, Inc., Annual General Meeting, May 31, 2024

Chief Medical Officer recently bought US$140k worth of stock

Chief Medical Officer recently bought US$189k worth of stock

Perspective Therapeutics, Inc., Annual General Meeting, Oct 06, 2023

Recent updates

CFO & Co-Principal Financial Officer recently bought US$177k worth of stock

CEO & Director recently bought US$117k worth of stock

Perspective Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $79.998535 million.

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Perspective Therapeutics, Inc. to Report Q1, 2024 Results on May 15, 2024

New minor risk - Profitability

No longer forecast to breakeven

Full year 2023 earnings released: US$0.14 loss per share (vs US$0.10 loss in FY 2022)

Perspective Therapeutics, Inc., Annual General Meeting, May 31, 2024

Perspective Therapeutics, Inc. announced that it has received $87.409482 million in funding from Lantheus Holdings, Inc.

Perspective Therapeutics, Inc. announced that it expects to receive $87.409482 million in funding from Lantheus Holdings, Inc. and other investors

Perspective Therapeutics, Inc. (NYSEAM:CATX) completed the acquisition of Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey from Progenics Pharmaceuticals, Inc.

Perspective Therapeutics, Inc. Introduces Pre-Targeting Theranostic Technology Platform

Chief Medical Officer recently bought US$140k worth of stock

Forecast to breakeven in 2026

Perspective Therapeutics, Inc. announced that it has received $20.846671 million in funding from Lantheus Alpha Therapy, LLC

Perspective Therapeutics, Inc. announced that it expects to receive $20.8 million in funding

Perspective Therapeutics, Inc. has completed a Follow-on Equity Offering.

Chief Medical Officer recently bought US$189k worth of stock

Perspective Therapeutics, Inc. Announces First Patient Dosed in A Phase 1 Study Of212pb)Vmt-A-Net to Treat Refractory or Relapsed Neuroendocrine Tumors

Perspective Therapeutics, Inc. Announces First Ever Human SPECT Imaging of Pb-212 with VMT-a-NET by Clinical Collaborators in Germany

Perspective Therapeutics, Inc. Announces Publication of Four Preclinical Studies in Peer-Reviewed Journals

New major risk - Financial position

Perspective Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Perspective Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Third quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Perspective Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2A Study of [(212)Pb VMT-a-Net for Treatment of Advanced SSTR2-Positive Neuroendocrine Tumors

Perspective Therapeutics, Inc. Announces Two Upcoming Investigator-Initiated Trials

Perspective Therapeutics, Inc. Announces Presentation of Positive Early Clinical Data for VMT-a-NET at 36th Annual Congress of European Association of Nuclear Medicine

Perspective Therapeutics, Inc. Presents Positive Preclinical Alpha Particle Therapy Data at the World Molecular Imaging Congress 2023 and the 36th Annual Congress of the European Association of Nuclear Medicine

Perspective Therapeutics, Inc., Annual General Meeting, Oct 06, 2023

New major risk - Financial position

Perspective Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of VMT01 of its Targeted Alpha-Particle Therapy (TAT), for Treatment of MC1R-positive Metastatic Melanoma

Second quarter 2023 earnings released

Perspective Therapeutics, Inc. Announces Termination of Jennifer Streeter as Chief Operating Officer

Less than half of directors are independent

Perspective Therapeutics, Inc.'s Cesium-131 Features at the American Brachytherapy Society's Annual Conference

Perspective Therapeutics, Inc. Initiates Phase 1/2a Clinical Trials for Two Targeted Alpha Therapy Oncology Product Candidates

Less than half of directors are independent

Perspective Therapeutics, Inc. Announces Changes to the Board of Directors

First quarter 2023 earnings released: US$0.002 loss per share (vs US$0.009 loss in 1Q 2022)

Chairperson of the Board exercised options to buy US$129k worth of stock.

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Isoray, Inc. Announces Termination of William Cavanagh III as Chief Research and Development Officer

Isoray, Inc. Announces Executive Changes

Isoray, Inc., Annual General Meeting, Jan 12, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Isoray, Inc. to Report Q1, 2023 Results on Nov 10, 2022

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Isoray, Inc. (NYSEAM:ISR) entered into an Agreement and Plan of Merger to acquire Viewpoint Molecular Targeting, Inc.

Isoray, Inc. to Report Q4, 2022 Results on Sep 28, 2022

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

No longer forecast to breakeven

Isoray, Inc. to Report Q3, 2022 Results on May 10, 2022

Price target decreased to US$1.47

Insufficient new directors

Consensus EPS estimates fall by 15%

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

CEO & Director exercised options to buy US$64k worth of stock.

No longer forecast to breakeven

First quarter 2022 earnings released: US$0.016 loss per share (vs US$0.01 loss in 1Q 2021)

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

マネジメント基準チェック /14